国药股份：12月9日召开董事会会议

Group 1 - The core point of the article is that China National Pharmaceutical Group Corporation (国药股份) held its 33rd meeting of the 8th Board of Directors on December 9, 2025, to discuss various proposals, including adjustments to the Board's specialized committee members [1] - For the fiscal year 2024, the revenue composition of China National Pharmaceutical Group is as follows: pharmaceutical commerce accounts for 104.55%, pharmaceutical manufacturing for 0.93%, warehousing and logistics for 0.78%, other businesses for 0.19%, and internal offsets for -6.45% [1] - As of the report date, the market capitalization of China National Pharmaceutical Group is 21.8 billion yuan [1] Group 2 - The article also highlights a significant issue in the pharmaceutical industry regarding the abuse of pregabalin, marking the first reported case of addiction in China, which raises concerns about the accessibility of prescription drugs without proper medical records [1]